Our pipeline

We have an exciting and balanced pipeline underpinned by great science.

Latest quarterly updates

Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.


166

projects in our pipeline

9

new molecular entities in our late-stage pipeline



Phase III/LCM Projects: refers to assets that are pivotal in Phase II/III, or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets (removed when launched in all applicable major markets).

Filter By:

Oncology (as at 30 July 2020)

Phase I

Phase I

  • AZD0466 haematological and solid tumours
  • AZD1390 glioblastoma
  • AZD4573 haematalogical malignancies
  • AZD5153 solid tumours, haematological malignancies
  • AZD5991 haematalogical malignancies
  • AZD7648 haematological and solid tumours
  • AZD9496 oestrogen receptor +ve breast cancer
  • Calquence (platform) PRISM relapsed/refractory aggressive non-hodgkin’s lymphoma
  • Calquence + ceralasertib haematological malignancies
  • Imfinzi + adavosertib solid tumours
  • Imfinzi + Koselugo (selumetinib) solid tumours
  • Imfinzi + RT (platform) CLOVER locally-advanced head and neck squamous cell carcinoma, non-small cell lung cancer, small-cell lung cancer
  • Imfinzi + tremelimumab solid tumours
  • Imfinzi + tremelimumab + CTx 1st-line pancreatic ductal adenocarcinoma, oesophageal and small cell lung cancer
  • IPH5201 solid tumours
  • MEDI1191 solid tumours
  • MEDI2228 multiple myeloma
  • MEDI5395 solid tumours
  • oleclumab + Tagrisso EGFRm non-small cell lung cancer

Phase II

Phase II

  • (oleclumab+CTx) or (Imfinzi+oleclumab+CTx) metastatic pancreatic cancer
  • adavosertib ovarian cancer, solid tumours
  • AZD2811 nanoparticle solid tumours, haematological malignancies
  • AZD4635 prostate cancer
  • AZD9833 oestrogen receptor +ve breast cancer
  • capivasertib prostate cancer
  • Imfinzi (platform) COAST non small cell lung cancer
  • Imfinzi (platform) HUDSON post IO non-small cell lung cancer
  • Imfinzi (platform) NeoCOAST non-small cell lung cancer
  • Imfinzi + AZD4635 prostate cancer
  • Imfinzi + FOLFOX + bevacizumab COLUMBIA 1 1st-line metastatic microsatellite-stable colorectal cancer
  • Imfinzi + Lynparza BAYOU 1st-line unresectable stage IV bladder cancer
  • Imfinzi + Lynparza ORION 1st-line metastatic non-small cell lung cancer
  • Imfinzi + MEDI0457 head and neck squamous cell carcinoma
  • Imfinzi + monalizumab solid tumours
  • Imfinzi + oleclumab solid tumours
  • Imfinzi + tremelimumab biliary tract, oesophageal
  • Imfinzi + tremelimumab gastric cancer
  • Lynparza + ceralasertib VIOLETTE breast cancer
  • Lynparza + Imfinzi MEDIOLA ovarian cancer, breast cancer, gastic cancer and small-cell lung cancer
  • MEDI5752 solid tumours
  • oleclumab + AZD4635 prostate cancer
  • Post-1L Tagrisso ORCHARD (platform) EGFRm non-small cell lung cancer
  • Tagrisso + or selumetinib or savolitinib) TATTON advanced EGFRm non-small cell lung cancer
  • Tagrisso + savolitinib SAVANNAH advanced EGFRm non-small cell lung cancer

Phase III

Phase III

  • capivasertib + CTx CAPItello-290 1st-line metastatic triple negative breast cancer
  • capivasertib + fulvestrant CAPItello-291 locally advanced (inoperable) or metastatic breast cancer
  • Enhertu DESTINY-Breast01 HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with T-DM1
  • Imfinzi + tremelimumab HIMALAYA 1st-line hepatocellular carcinoma
  • Imfinzi + tremelimumab KESTREL 1st-line head and neck squamous cell carcinoma
  • Imfinzi + tremelimumab + SoC NILE 1st-line urothelial cancer
  • Imfinzi +/- tremelimumab + CRT ADRIATIC 1st-line limited-stage small-cell lung cancer
  • Imfinzi +/- tremelimumab + CTx POSEIDON 1st-line non-small cell lung cancer
  • Koselugo/selumetinib SPRINT paediatric neurofibromatosis type-1
  • Lumoxiti 3rd-line hairy cell leukaemia
  • Lynparza + Imfinzi DUO-E 1st-line endometrial cancer
  • Lynparza + Imfinzi + bevacizumab DUO-O 1st-line ovarian cancer

2020欧洲杯体育足球滚球比分LCM Projects

LCM Projects

  • Calquence CALAVI-US & CALAVI-RoW COVID-19
  • Calquence ECHO 1st-line mantle cell lymphoma
  • Calquence ASCEND relapsed/refractory chronic lymphocytic leukaemia
  • Calquence ELEVATE-RR relapsed/refractory chronic lymphocytic leukaemia, high risk
  • Calquence ELEVATE-TN 1st-line chronic lymphocytic leukaemia
  • Calquence + venetoclax + obinutuzumab AMPLIFY 1st-line chronic lymphocytic leukaemia
  • Enhertu DESTINY-Breast03 HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane
  • Enhertu DESTINY-CRC01 HER2-expressing advanced colorectal cancer
  • Enhertu DESTINY-Gastric01 HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma patients who have progressed on two prior treatment regimens
  • Enhertu DESTINY-Gastric02 HER2-positive gastric cancer that cannot be surgically removed or has spread
  • Enhertu U204 HER2-over-expressing or -mutated, unresectable and/or metastatic non-small cell lung cancer
  • Enhertu DESTINY-Breast02 HER2-positive, unresectable and/or metastatic breast cancer pretreated with prior standard of care HER2 therapies, including T-DM1
  • Enhertu DESTINY-Breast04 HER2-low, unresectable and/or metastatic breast cancer subjects
  • Imfinzi CALLA locally-advanced cervical cancer
  • Imfinzi POTOMAC non muscle invasive bladder cancer
  • Imfinzi PACIFIC locally advanced (stage III) non-small cell lung cancer
  • Imfinzi PEARL 1st-line metastatic non-small cell lung cancer
  • Imfinzi (platform) BEGONIA 1st-line metastatic triple negative breast cancer
  • Imfinzi (platform) MAGELLAN 1st-line metastatic non-small cell lung cancer
  • Imfinzi + azacitidine myelodysplastic syndrome
  • Imfinzi + CRT PACIFIC-2 locally-advanced (stage III) non-small cell lung cancer
  • Imfinzi + CRT PACIFIC-5 (China) locally-advanced (stage III) non-small cell lung cancer
  • Imfinzi + CTx NIAGARA muscle invasive bladder cancer
  • Imfinzi + CTx TOPAZ-1 1st-line biliary tract cancer
  • Imfinzi + CTx neoadjuvant AEGEAN locally-advanced (stage I-III) non-small cell lung cancer
  • Imfinzi + SoC CASPIAN 1st-line extensive-stage small-cell lung cancer
  • Imfinzi + VEGF EMERALD-2 adjuvant hepatocellular carcinoma
  • Imfinzi + VEGF + TACE EMERALD-1 locoregional hepatocellular carcinoma
  • Imfinzi post-SBRT PACIFIC-4 stage I/II non-small cell lung cancer
  • Lynparza PROfound prostate cancer
  • Lynparza OlympiA gBRCA adjuvant breast cancer
  • Lynparza OlympiAD gBRCA metastatic breast cancer
  • Lynparza POLO pancreatic cancer
  • Lynparza SOLO-3 gBRCA PSR ovarian cancer
  • Lynparza (basket) MK-7339-002 / LYNK002 HRRm cancer
  • Lynparza + abiraterone PROpel prostate cancer
  • Tagrisso ADAURA adjuvant EGFRm non-small cell lung cancer
  • Tagrisso LAURA stage 3 EGFRm non-small cell lung cancer
  • Tagrisso + CTx FLAURA2 1st-line advanced EGFRm non-small cell lung cancer

Cardiovascular, Renal and Metabolism (as at 30 July 2020)

Phase I

Phase I

  • AZD2373 nephropathy
  • AZD2693 NASH
  • AZD6615 CV disease
  • AZD8233 CV disease
  • AZD9977 CV disease
  • MEDI6570 cardiovascular disease

Phase II

Phase II

  • AZD4831 heart failure with a preserved ejection fraction
  • AZD5718 coronary artery disease
  • AZD8601 cardiovascular disease
  • cotadutide type-2 diabetes, obesity and NASH
  • MEDI3506 diabetic kidney disease
  • MEDI5884 cardiovascular disease
  • MEDI6012 cardiovascular disease
  • verinurad chronic kidney disease

Phase III

Phase III

  • Epanova severe hypertriglyceridaemia
  • Lokelma hyperkalaemia
  • roxadustat OLYMPUS ROCKIES anaemia in chronic kidney disease/end-stage renal disease

2020欧洲杯体育足球滚球比分LCM Projects

LCM Projects

  • Brilinta/Brilique THALES acute ischaemic stroke or transient ischaemic attack
  • Brilinta/Brilique THEMIS cardiovascular outcomes trial in patients with coronary artery disease and type-2 diabetes without a previous history of myocardial infarction or stroke
  • Bydureon BCise (autoinjector) type-2 diabetes
  • Farxiga/Forxiga Dapa-CKD renal outcomes and cardiovascular mortality in patients with chronic kidney disease
  • Farxiga/Forxiga Dapa-HF worsening heart failure or cardiovascular death in patients with chronic heart failure (HFrEF)
  • Farxiga/Forxiga DECLARE- TIMI 58 cardiovascular outcomes trial in patients with type-2 diabetes
  • Farxiga/Forxiga DELIVER worsening HF or CV death in patients with chronic heart failure (HFpEF)
  • Farxiga/Forxiga DEPICT type-1 diabetes
  • Farxiga/Forxiga DETERMINE-Preserved heart failure with preserved ejection fraction (HFpEF)
  • Farxiga/Forxiga DETERMINE-Reduced heart failure with reduced ejection fraction (HFrEF)
  • Qternmet XR/Qtrilmet (saxagliptin/dapagliflozin metformin) type-2 diabetes
  • roxadustat anaemia in myelodysplastic syndrome
  • roxadustat chemotherapy induced anaemia
  • Xigduo XR/Xigduo type-2 diabetes

Respiratory & Immunology (as at 30 July 2020)

Phase I

Phase I

  • AZD0284 psoriasis/respiratory
  • AZD0449 asthma
  • AZD1402 asthma
  • AZD5634 cystic fibrosis
  • AZD8154 asthma
  • MEDI5117 China rheumatoid arthritis

Phase II

Phase II

  • abediterol asthma/chronic obstructive pulmonary disease
  • anifrolumab lupus nephritis
  • anifrolumab systemic lupus erythematosus (subcutaneous)
  • AZD7986 chronic obstructive pulmonary disease
  • AZD9567 rheumatoid arthritis/respiratory
  • brazikumab ulcerative colitis
  • MEDI3506 COPD/atopic dermatitis/asthma/COVID-19
  • navafenterol chronic obstructive pulmonary disease
  • tezepelumab atopic dermatitis
  • tezepelumab chronic obstructive pulmonary disease
  • velsecorat asthma/chronic obstructive pulmonary disease

Phase III

Phase III

  • anifrolumab TULIP systemic lupus erythematosus
  • AZD1222 (ChAdOx1 nCoV-19) COVID vaccine
  • Bevespi Aerosphere (PT003) chronic obstructive pulmonary disease
  • brazikumab crohns disease
  • Breztri Aerosphere (PT010) chronic obstructive pulmonary disease
  • Fasenra CALIMA SIROCCO ZONDA BISE BORA GREGALE MIRACLE severe uncontrolled asthma
  • nirsevimab passive RSV immunisation
  • PT027 asthma
  • tezepelumab NAVIGATOR SOURCE severe uncontrolled asthma

LCM Projects

LCM Projects

  • Breztri (PT010) asthma
  • Duaklir Genuair chronic obstructive pulmonary disease
  • Fasenra MANDARA eosinophilic granulomatosis with polyangiitis
  • Fasenra NATRON hypereosinophilic syndrome
  • Fasenra OSTRO ORCHID (Japan/China) nasal polyposis
  • Fasenra RESOLUTE chronic obstructive pulmonary disease
  • Symbicort SYGMA as-needed use in mild asthma

Other (as at 30 July 2020)

Phase I

Phase I

  • AZD4041 opioid use disorder
  • MEDI0618 osteoarthritis pain
  • MEDI1341 parkinson's disease
  • MEDI1814 alzheimer’s disease

Phase II

Phase II

  • MEDI7352 osteoarthritis pain and painful diabetic neuropathy
  • suvratoxumab prevention of nosocomial Staphylococcus aureus pneumonia

Phase III

Phase III

LCM Projects

LCM Projects

  • Nexium stress ulcer prophylaxis

Removed since last quarter

Veeva ID: Z4-12937     
Date of next review: September 2020